结直肠癌肝转移的治疗策略的研究应用与进展

吴 广斌
青海大学附属医院肝胆胰外科;青海省包虫病研究重点实验室

摘要


综合多学科的治疗手段已成为治疗结直肠癌肝转移的临床研究焦点，涵盖了手术、局部治疗、转化治疗、
化疗以及分子靶向药物治疗等多种策略。在实际临床操作中，通常需要将这些治疗方法结合起来，并根据患者的病
情定制全面的治疗方案，以期达到最佳的生存效益。因此，掌握目前临床治疗中常用方法的最新研究成果对于指导
治疗选择至关重要。

关键词


结直肠癌肝转移；外科手术；化疗；分子靶向治疗

全文:

PDF


参考


[1]XI Y, XU P. Global colorectal cancer burden in 2020

and projections to 2040.Transl Oncol. 2021;14(10):101174.

[2]刘媛媛，杨锐，宋奇科，等.结直肠癌肝转移瘤

影像特征与病理关系及预后评价 [J].中国临床医学影像杂

志，2022，33（3）：193— 196.

[3]Tauriello DV,Calon A,Lonardo E,et al.Determinants

of metastatic competency in colorectal cancer [J].Mol

Oncol,2017,11(1):97-119.DOI:10.1002/1878-0261.12018.

[4]张炜力，周驰，邓宇翔，等.初始不可切除结直

肠癌肝转移转化治疗结局影响因素分析 [J].中华胃肠外科

杂志，2022，25（1）：56— 62.

[5]Fontana R, Hermam P, Pugliese V, et al. Surgical

outcomes and prognostic factors in patients with synchronous

colorectal liver metastases[J]. Arq Gastroenterol, 2014,51(1)：

4-9.

[6]Germani MM, Borelli B, Boraschi P, et al. The

management of colorectal liver metastases amenable of

surgical resection: How to shape treatment strategies

according to clinical, radiological, pathological and molecular

features. Cancer Treat Rev. 2022;106:102382. doi:10.1016/

j.ctrv.2022.102382

[7]Liu M, Bao Q, Zhao T, et al. Pre-hepatectomy

dynamic circulating tumor DNA to predict pathologic

response to preoperative chemotherapy and post-hepatectomy

recurrence in patients with colorectal liver metastases. Hepatol

Int. 2024;18(3):1029-1039. doi:10.1007/s12072-023-

10628-4

[8]Chen Q, Deng Y, Li Y, et al. Association of

preoperative aspartate aminotransferase to platelet ratio

index with outcomes and tumour microenvironment

among colorectal cancer with liver metastases. Cancer Lett.

2024;588:216778. doi:10.1016/j.canlet.2024.216778

[9]李晶晶，廖晓琴，吴继萍，等.CAPIRI方案治疗

老年转移性结直肠癌一线 FOLFOX方案治疗失败患者的

临床分析 [J].老年医学与保健，2021，27（5）：1076—

1079，1085.

[10]Datta J, Narayan RR, Goldman DA, et al. Distinct

Genomic Profiles are Associated With Conversion to

Resection and Survival in Patients With Initially Unresectable

Colorectal Liver Metastases Treated With Systemic and

Hepatic Artery Chemotherapy. Ann Surg. 2022;276(5):e474-

e482. doi:10.1097/SLA.0000000000004613

[11 ]H ay a shi M , Inoue Y , Kome d a K ,et al.

Clinicopathological analysis of recurrence patterns and factors

for suivival after hepatectomy for colorectal liver metastasis[J].

BMC Surg, 2010,10：27.

[12]Gruber-Rouh T , Naguib NN , Eichler K ,et al.

Transarterial chemoembolization of unresectable systemic

chemotherapy-refractory liver metastases fromcolorectal

cancer: long-term results over a 10-year period[J]. Int J

Cancer, 2014,134(5)：1225-1231.

[13]Raphael MJ, Karanicolas PJ. Regional Therapy for

Colorectal Cancer Liver Metastases: Which Modality and

When?. J Clin Oncol. 2022;40(24):2806-2817. doi:10.1200/

JCO.21.02505

[14]Gholami S, Kemeny NE, Boucher TM, et al.

Adjuvant Hepatic Artery Infusion Chemotherapy is Associated

With Improved Survival Regardless of KRAS Mutation

Status in Patients With Resected Colorectal Liver Metastases:

A Retrospective Analysis of 674 Patients. Ann Surg.

2020;272(2):352-356. doi:10.1097/SLA.0000000000003248

[15]Hendisz A , Van den Eynde M , Peeters M ,et al.

Phase Ⅲ trail comparing protracted intravenous flurouracil

infusion alone or with yttrium-90 resin microspheres

135

现代医学前沿 | 第2卷/第11期

Advances in Mordern Medical

radioembolization for liver-limited metastastic colorectal

cancer refractory to standard chemothetapy[J]. J Clin Oncol,

2010,28(23)：3687-3694.

[16]Benson AB , Geschwind JF , Mulcahy MF ,et al.

Radioembolisation for liver metastases：Results from a

prospective 151 patient multi-institutional phase Ⅱ study[J].

Eur J Cancer, 2013,49(15)：3122-3130.

[17]Dabrowiecki A, Sankhla T, Shinn K, et al. Impact

of Genomic Mutation and Timing of Y90 Radioembolization

in Colorectal Liver Metastases. Cardiovasc Intervent Radiol.

2020;43(7):1006-1014. doi:10.1007/s00270-020-02463-z

[18]Alsultan AA, van Roekel C, Barentsz MW, et al.

Dose-Response and Dose-Toxicity Relationships for Glass

90Y Radioembolization in Patients with Liver Metastases

from Colorectal Cancer. J Nucl Med. 2021;62(11):1616-

1623. doi:10.2967/jnumed.120.255745

[19 ]Mohamad I, Barry A, Daw son L, Ho sni A.

Stereotactic body radiation therapy for colorectal liver

metastases. Int J Hyperthermia. 2022;39(1):611-619. doi:10.1

080/02656736.2021.1923836

[20]van der Lei S, Dijkstra M, Nieuwenhuizen S, et al.

Unresectable Intermediate-Size (3-5 cm) Colorectal Liver

Metastases: Stereotactic Ablative Body Radiotherapy Versus

Microwave Ablation (COLLISION-XL): Protocol of a Phase

II/III Multicentre Randomized Controlled Trial. Cardiovasc

Intervent Radiol. 2023;46(8):1076-1085. doi:10.1007/

s00270-023-03498-8

[21]Li J, Liu G, Xie X, et al. Outcomes Following

Different Thermal Ablation Strategies in Patients with

Unresectable Colorectal Liver Metastases. Radiology.

2023;308(2):e223135. doi:10.1148/radiol.223135

[22 ]Schullian P, John ston EW, Putzer D, et al.

Stereotactic radiofrequency ablation (SRFA) for recurrent

colorectal liver metastases after hepatic resection. Eur J Surg

Oncol. 2021;47(4):866-873. doi:10.1016/j.ejso.2020.09.034

[23]Laimer G, Jaschke N, Schullian P, et al. Volumetric

assessment of the periablational safety margin after thermal

ablation of colorectal liver metastases [published correction

appears in Eur Radiol. 2022 Jan;32(1):737. doi: 10.1007/

s00330-021-08107-1]. Eur Radiol. 2021;31(9):6489-6499.

doi:10.1007/s00330-020-07579-x

[24]Boilève A, De Cuyper A, Larive A, et al. Hepatic

arterial infusion of oxaliplatin plus systemic chemotherapy

and targeted therapy for unresectable colorectal liver

metastases. Eur J Cancer. 2020;138:89-98. doi:10.1016/

j.ejca.2020.07.022

[25]Wang DS, Ren C, Li SS, et al. Cetuximab plus

FOLFOXIRI versus cetuximab plus FOLFOX as conversion

regimen in RAS/BRAF wild-type patients with initially

unresectable colorectal liver metastases (TRICE trial): A

randomized controlled trial. PLoS Med. 2024;21(5):e1004389.

Published 2024 May 10. doi:10.1371/journal.pmed.1004389

[26]Heinemann V , von Weikersthal LF , Decker

T ,et al. FOLFIRI plus cetuximab versus FOLFIRI plus

bevacizumab as first-line treatment for patients with metastatic

colorectal cancer (FIRE-3): a randomised, open-label, phase

3 trial[J]. Lancet Oncol, 2014,15(10)：1065-1075.

[27]Chen YX , Yang Q , Kuang JJ ,et al. Efficacy

of adding bevacizumab in the first-line chemotherapy of

metastatic colorectal cancer: evidence from seven randomized

clinical trials[J]. Gastroenterol Res Pract, 2014,2014：594930.

[28]Yang YH , Lin JK , Chen WS ,et al. Comparison

of cetuximab to bevacizumab a s the first-line biochemotherapy for patients with metastatic colorectal cancer:

Superior progression-free survival is restricted to patients

with measurable tumors and objective tumor response-a

retrospective study[J]. Cancer Res Clin Oncol, 2014,140(11)：

1927-1936.

[29]Loupakis F , Cremolini C , Salvatore L ,et al.

FOLFOXIRI plus bevacizumab as first-line treatment in

BRAF mutant metastatic colorectal cancer[J]. Eur J Cancer,

2014,50(1)：57-63.


Refbacks

  • 当前没有refback。